Clinical Trial Update: Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) [Phase 3]

View source ↗

Summary

Phase 3 trial update on deferiprone for Pantothenate Kinase-associated Neurodegeneration (PKAN) with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pantothenate Kinase-associated Neurodegeneration

Drugs mentioned

• Deferiprone (deferiprone)

Snippet

Sponsor: ApoPharma | Conditions: Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Status: COMPLETED | Results posted: 2019-05-23